Request availability and a quotation for your required quantity and destination.
| Product | Dutasteride 0.5 mg - Avodart |
|---|---|
| Categories | Hair Care |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Product category: Hair Care · Prescription medicine information & enquiries
Ingredient: Dutasteride 0.5 mg
Class: 5-alpha-reductase inhibitor
Form: Oral capsule
Status: Prescription medicine
Avodart is approved in the United States for symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. Dutasteride inhibits type 1 and type 2 5-alpha-reductase, reducing conversion of testosterone to dihydrotestosterone (DHT). It is sometimes prescribed off-label for androgenetic alopecia, but hair-loss use should not be represented as the U.S. approved indication.
DHT contributes to follicular miniaturization in androgenetic alopecia. A dermatology specialist should assess diagnosis, alternatives, fertility concerns, contraindications and the risks of systemic DHT suppression before discussing off-label treatment.
Potential adverse reactions include reduced libido, erectile or ejaculation problems and breast tenderness or enlargement. Dutasteride lowers prostate-specific antigen (PSA), affecting prostate-cancer screening interpretation. Labeling warns of a possible increased risk of high-grade prostate cancer and instructs pregnant people, or those who may become pregnant, not to handle leaking capsules. Do not donate blood until at least six months after the final dose. Discuss possible interactions with potent CYP3A4 inhibitors.
Finasteride 1 mg – Finalo is a separate 5-alpha-reductase inhibitor; these medicines should not be combined or substituted without professional advice.
DailyMed: Avodart prescribing information
For its approved BPH indication, changes in urinary symptoms may take months. Hair-growth use is off-label, and response varies.
Dutasteride inhibits both type 1 and type 2 5-alpha-reductase whereas finasteride primarily inhibits type 2. That does not establish the best treatment for an individual.
Yes. Reduced libido, erectile difficulties and ejaculation problems are reported adverse effects.
Changes in semen parameters have been reported. Discuss fertility plans with a prescribing clinician.
Pregnant people or those who may become pregnant should not handle leaking capsules because dutasteride may harm a developing male fetus.
Different mechanisms do not mean a combination is appropriate for everyone. A dermatologist must assess possible benefits, contraindications and monitoring.
Any hair-related benefit from off-label treatment may diminish after cessation; follow-up with a clinician is advisable.
In the United States, Avodart is approved for BPH, not hair loss. Hair-loss use is off-label.
Yes. Tell the clinician interpreting your PSA results about dutasteride use.
No. A prescriber should review whether treatment is appropriate and the implications of stopping.
Cureiva handles lawful product enquiries subject to prescriptions, verification and destination-country requirements. Educational material, not individualized advice; no physician review is claimed. Updated October 2026.